Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

FDA Releases Annual Report on the State of Pharmaceutical Quality and Global Site Surveillance

FDA’s CDER Office of Pharmaceutical Quality updated its annual surveillance report detailing global drug manufacturing compliance and testing outcomes.

Medically reviewed byDr. Diana Nieves Castro, MD
Published 21 Nov 2026· Last updated 21 Nov 2026· 7 minute read
Interior view of the FDA CDER Life Sciences Laboratory at the White Oak campus in Silver Spring, Maryland
Photo: The U.S. Food and Drug Administration / Wikimedia Commons, Public domain (cropped). Source

On November 20, 2026, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research released its annual surveillance report evaluating global drug manufacturing quality, foreign facility compliance, and retail product testing. The findings establish critical compliance benchmarks for clinical trial sponsors, academic medical centers, and pharmaceutical investigators navigating international supply chain risks, chemistry and manufacturing controls, and investigational drug integrity.

CDER Office of Pharmaceutical Quality Releases Global Surveillance Findings

The FDA Center for Drug Evaluation and Research (CDER) Office of Pharmaceutical Quality (OPQ) published its updated Report on the State of Pharmaceutical Quality, delivering an empirical assessment of manufacturing facility compliance, global supply chain demographics, and postmarket surveillance outcomes. The report aggregates data across CDER’s international Site Catalog, which inventories all registered active pharmaceutical ingredient (API) and finished dosage form facilities supplying the United States market. The regulatory report outlines how the agency applies risk-based analytics to identify systemic vulnerabilities in pharmaceutical distribution, monitor compliance with Current Good Manufacturing Practice (CGMP) regulations, and prevent manufacturing defects before they trigger clinical shortages.

According to the findings, CDER oversees a decentralized pharmaceutical manufacturing footprint. While domestic U.S. facilities comprise approximately 41% of the registered manufacturing catalog, more than 58% of all sites manufacturing human drugs for the American public are situated overseas, heavily concentrated in India, China, and Europe. The report highlights that foreign facility surveillance has expanded substantially through in-person audits, Mutual Recognition Agreements (MRAs) with international partner authorities, and remote regulatory records evaluations under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act.

Global Site Demographics, EAST Sampling, and Inspection Outcomes

A central pillar of the report focuses on physical laboratory surveillance under CDER’s Drug Quality Sampling and Testing Programs, particularly the Enhanced Approach for Sampling and Testing (EAST) initiative. Rather than relying exclusively on scheduled factory inspections, the EAST program procures commercial finished dosage forms directly from retail pharmacies, health systems, and wholesale distributors. Agency laboratories evaluate these samples against compendial standards, such as United States Pharmacopeia (USP) monographs, testing core quality attributes including active ingredient identity, potency assay, dissolution rates, and impurity degradation profiles.

The report details surveillance testing outcomes across finished pharmaceuticals and over-the-counter (OTC) products, tracking potential contaminants including industrial solvents (such as diethylene glycol and ethylene glycol) and nitrosamines. CDER’s targeted testing protocols confirmed that proactive screening successfully identified non-compliant product lots before widespread exposure occurred. Concurrently, the agency evaluated compliance trends across Biologics License Applications (BLAs), noting that biosimilars now account for over 40% of approved biologic drug filings, requiring heightened analytical characterization and lifecycle manufacturing controls.

The quantitative dimensions of CDER’s pharmaceutical quality surveillance framework encompass facility oversight, direct commercial testing, and international compliance auditing:

Surveillance Domain Operational Scope Core Regulatory Focus Primary Risk Mitigation Outcome
Global Site Catalog 4,600+ registered facilities Domestic (41%) and foreign (59%) manufacturing coverage Prioritizes risk-based surveillance inspection assignments
EAST Sampling and Testing Direct commercial procurement Identity, assay potency, dissolution, and chemical impurities Validates commercial product quality independent of facility self-reporting
Foreign Inspection Oversight Over 60% of total audits On-site audits in India, China, and MRA partner nations Identifies severe CGMP breakdowns, preventing adulterated imports
Biologics and Biosimilars Rapidly expanding share Critical quality attribute comparability and process stability Ensures safe scale-up and commercial bioequivalence in therapeutic proteins

Post-Pandemic Inspection Acceleration and Supply Chain Pressures

The multi-year trajectory documented in the report reflects a sustained recovery in FDA field inspection activity following the disruptions of the COVID-19 pandemic. CDER reported a notable resurgence in surveillance audits, with foreign inspection counts exceeding historical baselines. To supplement physical facility visits, the FDA expanded statutory records requests under Section 704(a)(4), with nearly three-quarters of all pre-approval records requests directed at international manufacturing establishments.

The surveillance data also illuminates the direct relationship between manufacturing quality lapses and therapeutic supply disruptions. As detailed on the site’s reference guide to the fda drug shortage list, the majority of critical drug shortages in the United States stem from manufacturing quality defects, particulate contamination, and facility compliance shutdowns rather than shifts in clinical demand. Facilities that experience severe CGMP breakdowns frequently encounter Official Action Indicated (OAI) inspection classifications, triggering application withholds, import alerts, and warning letters. Furthermore, CDER’s findings underscore the value of rigorous internal quality reviews, aligning with standard frameworks analyzed in CASRAI’s guide to the annual product quality review apqr, which mandates that drug makers systematically evaluate batch manufacturing records, stability trends, and out-of-specification investigations on an annual schedule.

Regulatory Affairs and Quality Systems Analysis

Independent regulatory and industry analysts have examined CDER’s surveillance metrics, highlighting progress alongside persistent vulnerabilities across the global supply network. In an analytical review, the Regulatory Affairs Professionals Society emphasized that while the FDA’s inspection rebound represents a major achievement in foreign oversight, warning letter trends continue to reveal recurring deficiencies in Quality Control Unit oversight, data integrity protocols, and aseptic processing validation.

From the perspective of international compliance monitoring, the European Compliance Academy via ECA Academy noted that facilities dedicated to essential medicine production generally exhibit higher compliance ratings than non-application over-the-counter sites, though geographic concentration in specific overseas manufacturing hubs remains a structural risk. Additionally, legal commentators at Frost Health Law observed that CDER’s expansion of the EAST program marks an operational transition toward direct market surveillance, warning manufacturers that product testing data obtained at retail pharmacies can directly trigger unannounced facility audits, import detentions, and mandatory recall actions.

Implications for Investigational Drug Supply, CMC Compliance, and Research Pharmacies

The findings presented in the CDER pharmaceutical quality report carry operational ramifications for academic medical centers, university research offices, and clinical investigators managing clinical trial materials. Investigational Medicinal Products and trial supplies are frequently sourced from contract development and manufacturing organizations (CDMOs) located across international jurisdictions. Research administrators and trial sponsors must recognize that foreign manufacturing sites with unaddressed CGMP violations face heightened risks of regulatory holds or import alerts, which can abruptly disrupt active clinical trials.

To maintain investigational drug supply continuity and satisfy Chemistry, Manufacturing, and Controls (CMC) requirements, research institutions must implement thorough supplier qualification programs. Clinical trial sponsors preparing Investigational New Drug (IND) applications should verify that prospective CDMOs possess spotless inspection histories and do not employ individuals or entities listed on federal exclusion registries, as detailed in the reference guide to the fda debarment list. Academic trial offices must require comprehensive Certificates of Analysis, audit laboratory validation packages, and establish secondary sourcing pathways for critical study formulations.

For institutional research pharmacies, investigational drug services, and principal investigators, CDER’s enhanced sampling and defect monitoring signals an urgent need for proactive inventory oversight. Research pharmacists should establish standard procedures to cross-reference investigational stocks against FDA warning letters, import alerts, and voluntary recall notices. Verifying storage temperature monitoring logs, cold chain documentation, and lot-specific potency data ensures that investigational compounds administered to clinical trial participants meet rigorous standards of safety, purity, and therapeutic consistency.

Next Steps for Quality Management Maturity and Expanded Surveillance

Looking ahead, CDER plans to advance its postmarket surveillance framework by expanding the Quality Management Maturity (QMM) program. While baseline CGMP compliance establishes minimum legal requirements for manufacturing, the QMM initiative evaluates manufacturers based on organizational commitment to continuous improvement, advanced quality culture, supply chain transparency, and proactive risk management. CDER anticipates that formalizing a QMM rating mechanism will incentivize voluntary industry investment in modern manufacturing infrastructure, providing clinical researchers with transparent insight into supplier reliability.

Additionally, the FDA is scheduled to broaden its EAST sampling protocols throughout the coming fiscal year, incorporating advanced spectroscopic screening technologies, rapid portable testing kits, and enhanced statistical sampling models. CDER will also continue deepening bilateral cooperation under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and international harmonization platforms, including implementation of updated ICH Q9(R1) guidelines on quality risk management. For biopharmaceutical developers, clinical research sponsors, and academic health systems, staying aligned with CDER’s quality surveillance landscape will remain essential for regulatory compliance, trial integrity, and participant safety.

Sources

Ask CASRAI · full access

Ask about this story

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →